SCHEMBL810263

SCHEMBL810263

CCCc1ccc2c(Nc3cc(C)ccc3Sc3cccc(O)c3)ncnc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.47
AKT2 P31751 1/20 0.47
HTT P42858 2/20 0.35
SREBF2 Q12772 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
RET P07949 1/20 0.33
KIF5B P33176 1/20 0.33
KDR P35968 1/20 0.33
POLB P06746 1/20 0.33
EGFR P00533 3/20 0.32
TTBK1 Q5TCY1 1/20 0.32
HSD17B10 Q99714 1/20 0.32
FGFR1 P11362 1/20 0.32
GAA P10253 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811175 0.90 PIM1 (0.56) PIM1AKT2HTTSREBF2KDM4E
SCHEMBL810548 0.89 PIM1 (0.49) PIM1AKT2HTTKDM4EMEN1
SCHEMBL2965230 0.87 SREBF2 (0.37) PIM1AKT2SREBF2KDM4ERET
SCHEMBL5065533 0.84 PIM1 (0.45) PIM1AKT2HTTKDM4EMEN1
SCHEMBL811120 0.83 PIM1 (0.44) PIM1AKT2HTTRETKIF5B
SCHEMBL810890 0.82 PIM1 (0.49) PIM1AKT2HTTKDM4EMEN1
SCHEMBL810616 0.82 PIM1 (0.44) PIM1AKT2SREBF2KDM4EMEN1
SCHEMBL810905 0.78 PIM1 (0.42) PIM1AKT2HTTKDM4EMEN1
SCHEMBL811431 0.77 PIM1 (0.66) PIM1AKT2HTTKDM4EMEN1
SCHEMBL810954 0.77 PIM1 (0.58) PIM1AKT2HTTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885HTT 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.